Phase III trial for KLU156 (ganaplacide/lumefantrine, or GanLum), meets primary endpoint of non-inferiority to standard of care Coartem® (artemether-lumefantrine) Demonstrates PCR-corrected cure rate ...
Phase III trial for KLU156 (ganaplacide/lumefantrine, or GanLum), meets primary endpoint of non-inferiority to standard of care Coartem® (artemether-lumefantrine) Demonstrates PCR-corrected cure rate ...
In 2022, the WHO hailed Novartis’ GanLum as the most promising non-artemisinin-based combination. The Swiss drugmaker ...
The study of GanLum (KLU156) – a combination of novel drug ganaplacide with established antimalarial lumefantrine – showed ...
As it presented final-stage trial results, Novartis said the new antimalarial drug it is developing is as effective as ...
Swiss drugmaker Novartis opens new manufacturing facility, part of operations expansion in the U.S. that will also invest ...
A new malaria drug, Ganaplacide/Lumefantrine, shows over 97% cure rates in trials. This treatment is effective even where ...
Switzerland-based Novartis has developed a new anti-malaria drug, GanLum, that showed 97% effectiveness in late-stage trials.
A new antimalarial drug developed by Novartis is as effective as existing treatments and could help tackle rising drug ...
Researchers are reporting two promising approaches to counteract malaria's growing drug resistance. Switzerland-based ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback